Xiaofei Wang

Xiaofei Wang

Auto-generated profile, based on publicly available information

Xiaofei Wang

Center for Pharmacogenetics, Department of Pharmaceutical Sciences, University of Pittsburgh, Pittsburgh, PA, USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 December 2022 in Science Advances
Verified
Journal Article
Open access
YWYifei Wang
Yifei Wang
YZYueshan Zhao
Yueshan Zhao
WGWeiwei Guo
Weiwei Guo
GYGhanshyam Singh Yadav
Ghanshyam Singh Yadav
CBChetana Bhaskarla
Chetana Bhaskarla
DYDa Yang
Da Yang
The majority of lncRNAs’ roles in tumor immunology remain elusive. This project performed a CRISPR activation screening of 9744 lncRNAs in melanoma cells cocultured with human CD8+T cells. We identified 16 lncRNAs potentially regulating tumor immune response. Further integrative analysis using tumor immunogenomics data revealed thatIL10RB-DTandLINC01198are significantly correlated with tumor immune response and survival in melanoma and breast cancer. Specifically,IL10RB-DTsuppresses CD8+T cells activation via inhibiting IFN-γ–JAK–STAT1 signaling and antigen presentation in melanoma and breast cancer cells. On the other hand,LINC01198’s up-regulation sensitizes the killing of tumor cells by CD8+T cells. Mechanistically,LINC01198interacts and activates NF-κB component p65 to trigger the type I and type II interferon responses in melanoma and breast cancer cells. Our study systematically characterized novel lncRNAs involved in tumor immune response.

1 June 2021 in Molecular and Cellular Endocrinology
Verified
Journal Article
Closed access
XWXiaofei Wang
Xiaofei Wang
DYDa Yang
Da Yang

12 August 2025 in Nature Structural & Molecular Biology
Verified
Journal Article
Closed access
XWXiaofei Wang
Xiaofei Wang
ZWZehua Wang
Zehua Wang
SLSihan Li
Sihan Li
DPDhamotharan Pattarayan
Dhamotharan Pattarayan
YWYifei Wang
Yifei Wang
DYDa Yang
Da Yang

12 August 2025 in Science Signaling
Verified
Journal Article
Closed access
DPDhamotharan Pattarayan
Dhamotharan Pattarayan
YWYue Wang
Yue Wang
ZWZehua Wang
Zehua Wang
SLSihan Li
Sihan Li
XWXiaofei Wang
Xiaofei Wang
DYDa Yang
Da Yang
Increases in retroelement-derived double-stranded RNAs (dsRNAs) in various types of cancer cells facilitate the activation of antitumor immune responses. The long noncoding RNA EPIC1 interacts with the histone methyltransferase EZH2 and contributes to tumor immune evasion. Here, we found that EPIC1 in tumor cells suppressed cytoplasmic dsRNA accumulation, type I interferon (IFN) responses, and antitumor immunity. In various cancer cell lines, knockdown of EPIC1 stimulated the production of dsRNA from retroelements and an antiviral-like type I IFN response that activated immune cells. EPIC1 inhibited the expression of LINE, SINE, and LTR retroelements that were also repressed by EZH2, suggesting a potential role for the EPIC1-EZH2 interaction in regulating dsRNA production. In a humanized mouse model, in vivo delivery of EPIC1-targeting oligonucleotides enhanced dsRNA accumulation in breast cancer xenografts, reduced tumor growth, and increased the infiltration of T cells and inflammatory macrophages into tumors. Furthermore, EPIC1 knockdown improved the therapeutic efficacy of the immunotherapy drug pembrolizumab, a PD-1 inhibitor, in the humanized mouse model. Together, our findings establish EPIC1 as a key regulator of dsRNA-mediated type I IFN responses and highlight its potential as a therapeutic target to improve the efficacy of immunotherapy.

24 April 2026 in Science Advances
Verified
Journal Article
Open access
SLSihan Li
Sihan Li
ZWZehua Wang
Zehua Wang
PNPhuong Nguyen
Phuong Nguyen
YWYue Wang
Yue Wang
YZYueshan Zhao
Yueshan Zhao
DYDa Yang
Da Yang
Emerging evidence suggests that MYC binds RNAs, but its functional consequences remain unclear. Here, we integrate multiomics data and reveal that MYC broadly binds enhancer RNAs (eRNAs), which exhibit high cancer- and tissue-specific expression in cancer cell lines and patient tumors. Moreover, we developed a computational pipeline to identify potential cis-regulatory MYC-eRNA target genes, with most predicted eRNA-target pairs supported by RNA polymerase II–mediated chromatin interaction data. Among these, we functionally characterized MERG1 as an oncogenic eRNA that promotes breast cancer tumorigenesis. Mechanistically, MERG1 interacts with MYC to enhance its occupancy at the GREB1 promoter, driving chromatin remodeling and epigenetic activation. This process specifically amplifies GREB1 expression and promotes tumor progression. Last, nanoparticle-mediated delivery of antisense oligonucleotides targeting MERG1 suppresses MYC-mediated breast cancer growth. These results advance our understanding of the enhancer-driven regulation of gene expression and tumorigenesis and provide insights into the regulatory landscape of MYC in cancer.

9 April 2026 in Nature Communications
Verified
Journal Article
Open access
PDF file
YWYifei Wang
Yifei Wang
YZYueshan Zhao
Yueshan Zhao
JHJiaxin Hu
Jiaxin Hu
ZWZehua Wang
Zehua Wang
DPDhamotharan Pattarayan
Dhamotharan Pattarayan
DYDa Yang
Da Yang
The roles of long non-coding RNAs (lncRNAs) in tumorigenesis and therapeutic response remain largely unknown. Here we perform genome-wide and focused CRISPR activation screens to identify lncRNAs regulating palbociclib response in breast cancer cells. A synchronized two-stage proliferation screen not only characterizes tumor growth-regulating lncRNAs, but also reveals a strong negative correlation between lncRNA-mediated regulation of tumor proliferation and CDK4/6 inhibitor sensitivity. By integrating CRISPRa screen results with drug response data from 815 cancer cell lines, we identify and functionally validate that TENM3-AS1, LINC01117, and ENSG00000226706 can increase breast cancer sensitivity to CDK4/6i while promoting tumor proliferation. In breast cancer patients, all three lncRNA signatures are associated with CDK4/6 inhibitor response. Mechanistically, we have shown that lncRNA TENM3-AS1 is a potential ERα-interacting lncRNA, and its regulation of CDK4/6 inhibitor sensitivity is dependent on ERα expression. Our integrated strategy characterizes oncogenic lncRNAs as potential therapeutic biomarkers for CDK4/6 inhibitor treatment in cancer.